Abstract:Background: Our knowledge of how to better manage elevated blood pressure (BP) in the presence of comorbidities is limited, in part due to exclusion or underrepresentation of patients with multiple chronic conditions from major clinical trials. We aimed to investigate the burden and types of comorbidities in patients with hypertension and to assess how such comorbidities and other variables affect BP levels over time. Methods and findings: In this multiple landmark cohort study, we used linked electronic health records from the United Kingdom Clinical Practice Research Datalink (CPRD) to compare systolic blood pressure (SBP) levels in 295,487 patients (51% women) aged 61.5 (SD = 13.1) years with first recorded diagnosis of hypertension between 2000 and 2014, by type and numbers of major comorbidities, from at least 5 years before and up to 10 years after hypertension diagnosis. Time-updated multivariable linear regression analyses showed that the presence of more comorbidities was associated with lower SBP during follow-up. In hypertensive patients without comorbidities, mean SBP at diagnosis and at 10 years were 162.3 mm Hg (95% confidence interval [CI] 162.0 to 162.6) and 140.5 mm Hg (95% CI 140.4 to 140.6), respectively; in hypertensive patients with ≥5 comorbidities, these were 157.3 mm Hg (95% CI 156.9 to 157.6) and 136.8 mm Hg (95% 136.4 to 137.3), respectively. This inverse association between numbers of comorbidities and SBP was not specific to particular types of comorbidities, although associations were stronger in those with preexisting cardiovascular disease. Retrospective analysis of recorded SBP showed that the difference in mean SBP 5 years before diagnosis between those without and with ≥5 comorbidities was -9 mm Hg (95% CI -9.7 to -8.3), suggesting that mean recorded SBP already differed according to the presence of comorbidity before baseline. Within 1 year after the diagnosis, SBP substantially declined, but subsequent SBP changes across comorbidity status were modest, with no evidence of a more rapid decline in those with more or specific types of comorbidities. We identified factors, such as prescriptions of antihypertensive drugs and frequency of healthcare visits, that can explain SBP differences according to numbers or types of comorbidities, but these factors only partly explained the recorded SBP differences. Nevertheless, some limitations have to be considered including the possibility that diagnosis of some conditions may not have been recorded, varying degrees of missing data inherent in analytical datasets extracted from routine health records, and greater measurement errors in clinical measurements taken in routine practices than those taken in well-controlled clinical study settings. Conclusions: BP levels at which patients were diagnosed with hypertension varied substantially according to the presence of comorbidities and were lowest in patients with multi-morbidity. Our findings suggest that this early selection bias of hypertension diagnosis at different BP levels was a key determinant of long-term differences in BP by comorbidity status. The lack of a more rapid decline in SBP in those with multi-morbidity provides some reassurance for BP treatment in these high-risk individuals.

The prevalence of hypertension in multiple sclerosis based on 37 million electronic health records from the United States

Association Between Migraine or Severe Headache and Hypertension among US Adults: A Cross-Sectional Study

Multi-morbidity and blood pressure trajectories in hypertensive patients: A multiple landmark cohort study

Abstract 136: Unsupervised Learning Using EHR Data to Detect Distinct Subphenotypes of Hypertension

Trajectories and management of vascular risk following the diagnosis of multiple sclerosis: A population-based matched cohort study between 1987 and 2018 in England

Trends in the Prevalence of Multiple Chronic Conditions Among US Adults With Hypertension From 1999–2000 Through 2017–2020

Blood Pressure and Body Fat Percent in Women with NMOSD.

Relevance of obesity-related organ damage and metabolic syndrome classification in cardiovascular and renal risk stratification in patients with essential hypertension

Prevalence and Mortality Trends of Hypertension Subtypes Among US Adults

Characterizing apparent treatment resistant hypertension in the United States: insights from the All of Us Research Program

Hypertension, uncontrolled hypertension and resistant hypertension: prevalence, comorbidities and prescribed medications in 228,406 adults resident in urban areas. A population-based observational study

Use of electronic health records to characterize patients with uncontrolled hypertension in two large health system networks

[Blood pressure control and influencing factors in hypertension patients with metabolic syndrome]

Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations

Prevalence of Masked Hypertension among US Adults with Nonelevated Clinic Blood Pressure.

Patients with Comorbid Coronary Artery Disease and Hypertension: a Cross-Sectional Study with Data from the NHANES

Increasing Prevalence of Hypertension in Low Income Residents Within Louisiana State University Health Care Services Division Hospital System

Impact of intensive hypertension criteria on multimorbidity prevalence and patterns in a multi-ethnic Chinese population

Stage B Heart Failure Is Ubiquitous in Emergency Patients with Asymptomatic Hypertension

Sex Differences in Hypertension and Its Management Throughout Life

Abstract 057: Trends In Blood Pressure Diagnosis, Treatment, And Control Among Nursing Home Residents, 2007-2018